BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
ENHERTU® approved in the US for two new indications for patients with HER2-positive early breast cancer
Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer
Perioperative IMFINZI® plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
TRUQAP® recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
ENHERTU® granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Providence Gold Reports Up to 8.0 g/t Au from Mojave Girl Phase 2 Evaluation of Tarantula Gold Mine Set to Begin
Metals Australia Limited Announces Participation in THE Mining Investment Event, Quebec City, June 2-4, 2026
